Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors

NCT02646748 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02646748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02646748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
January 25, 2016
Completion date
November 20, 2020
Enrollment
159 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer (crc), endometrial cancer, head and neck cancer, lung cancer, melanoma, mmr-deficient tumors, pancreatic cancer, renal cell carcinoma (rcc), solid tumors, uc (urothelial cancer)